AbCellera Biologics Inc vs United Microelectronics Corp — how do they compare? AbCellera Biologics Inc trades at $9.23 (market cap $2.99B), while United Microelectronics Corp trades at $19.85 (market cap $47.81B). The key difference: United Microelectronics Corp is far larger — about 16× AbCellera Biologics Inc's market cap, and United Microelectronics Corp pays a 2.12% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | UMC | |
|---|---|---|
Market Cap | $2.99B | $47.81B |
Sector | Health | Technology |
52-Week High | $9.76 | $28.02 |
52-Week Low | $2.78 | $6.58 |
Enterprise Value | $2.58B | $44.93B |
Dividend Yield | — | 2.12% |
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
UMC trades at $18.79, up 0.37% today, with a bearish technical signal. Recent earnings beats and strong July 2026 sales growth of 18.98% year-over-year highlight operational momentum. The company is expanding capacity in Singapore and Taiwan to meet AI-driven demand, supported by a robust balance sheet with $115.24 billion in cash. However, net income margin has declined from 32.1% in 2022 to 16.99% in 2025, posing a concern.
The outlook is mixed; expansion initiatives and AI tailwinds offer growth potential, but margin compression and a bearish technical stance present risks. Analyst consensus is cautious with 53.33% hold ratings. Key catalysts include Q3 2026 earnings and fab expansion progress, while competitive pressures and macroeconomic volatility remain headwinds.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →